LQDA Stock Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Liquidia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.48 |
| 52 Week High | US$16.99 |
| 52 Week Low | US$5.71 |
| Beta | 0.19 |
| 1 Month Change | -16.58% |
| 3 Month Change | -15.73% |
| 1 Year Change | 71.90% |
| 3 Year Change | 355.47% |
| 5 Year Change | 25.81% |
| Change since IPO | 12.43% |
Recent News & Updates
Recent updates
Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher
Jan 19
Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable
Dec 20Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?
Aug 17Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues
Mar 18Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?
Feb 06Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 25Liquidia: United Manages A Temporary Win
Sep 12Liquidia tumbles 33% after judge denies stay request in United Therapeutics patent dispute
Aug 30Liquidia Q2 2022 Earnings Preview
Aug 10Liquidia Vs. MannKind: Treprostinil Is The Big 'IF'
Jun 29Liquidia Corporation (NASDAQ:LQDA) Just Reported And Analysts Have Been Lifting Their Price Targets
May 15Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?
Mar 16Liquidia And United: The Tango Continues
Jan 18Shareholder Returns
| LQDA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.9% | 1.4% | 2.7% |
| 1Y | 71.9% | 12.9% | 26.0% |
Return vs Industry: LQDA exceeded the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: LQDA exceeded the US Market which returned 25% over the past year.
Price Volatility
| LQDA volatility | |
|---|---|
| LQDA Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LQDA's share price has been volatile over the past 3 months.
Volatility Over Time: LQDA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 145 | Roger Jeffs | www.liquidia.com |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.
Liquidia Corporation Fundamentals Summary
| LQDA fundamental statistics | |
|---|---|
| Market cap | US$954.78m |
| Earnings (TTM) | -US$78.50m |
| Revenue (TTM) | US$17.49m |
54.5x
P/S Ratio-12.1x
P/E RatioIs LQDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LQDA income statement (TTM) | |
|---|---|
| Revenue | US$17.49m |
| Cost of Revenue | US$2.89m |
| Gross Profit | US$14.60m |
| Other Expenses | US$93.10m |
| Earnings | -US$78.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -1.03 |
| Gross Margin | 83.49% |
| Net Profit Margin | -448.89% |
| Debt/Equity Ratio | 97.3% |
How did LQDA perform over the long term?
See historical performance and comparison